Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, May 21, 2018
[ 12:00 AM ] - WOPRAI
Fri, May 18, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, May 17, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, May 16, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Michelle Gilson Initiated (BMRN) at Strong Buy and Held Target at $101 on, May 16th, 2018
Michelle Gilson of Canaccord Genuity, Initiated "BioMarin Pharmaceutical Inc." (BMRN) at Strong Buy and Held Target at $101 on, May 16th, 2018.
Michelle has made no other calls on BMRN in the last 4 months.
There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 0 agree with Michelle's Rating of Hold.
These are the ratings of the 7 analyists that currently disagree with Michelle
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $113 on, Monday, April 30th, 2018
- Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $116 on, Friday, March 2nd, 2018
- Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $124 on, Friday, February 23rd, 2018
- Joseph Schwartz of "Leerink Swann" Maintained at Buy with Decreased Target to $132 on, Friday, February 23rd, 2018
- M. Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $125 on, Friday, February 23rd, 2018
- Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $102 on, Friday, February 23rd, 2018
- Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $129 on, Wednesday, January 24th, 2018
